Latest news with #YellowFever
Daily Mirror
2 days ago
- Health
- Daily Mirror
Alert as vaccine for travellers for lethal infection out of stock
The vaccine is expected to be out of stock for a number of weeks, Foreign Office website Travel Health Pro today reported Holidaymakers have been alerted to a disruption in the supply of a crucial vaccine, which is expected to be 'unavailable' for the next 2-3 weeks. Sanofi has informed NaTHNaC that there will be a shortage of the yellow fever vaccine Stamaril in the UK. The Foreign Office's Travel Health Pro website reported today that the vaccine is anticipated to be out of stock for 2-3 weeks. NaTHNaC (National Travel Health Network and Centre) is a UK organisation dedicated to safeguarding the health of British travellers. This means individuals travelling to certain regions globally will not be able to receive vaccination against this potentially deadly disease. The NHS warns: "Yellow fever is a serious infection spread by mosquitoes. It's found in certain areas of Africa and South and Central America. You should have a yellow fever vaccination if you're travelling to an area where there's a risk of getting it. Yellow Fever is a potentially fatal disease transmitted by mosqjuitos and turns wee dark, causes serious stomach pain, yellows the skin and eyes and bleeding from the eyes, nose, mouth or stomach - serious cases can be Foreign Office site said: ". Countries in Africa with Risk of Yellow fever Transmission: Angola, Equatorial Guinea, Mauritania, Benin, Ethiopia, Niger, Burkina Faso, Gabon, Nigeria, Burundi, Gambia, the Senegal, Cameroon, Ghana, Sierra Leone, Central African Republic, Guinea, South Sudan, Chad, Guinea-Bissau, Sudan, Congo, Republic of Kenya, Togo, Cote d'Ivoire, Liberia, Uganda, Democratic Republic of Congo, Mal Countries in Central and South America with Risk of Yellow Fever Transmission: Argentina, French Guiana, Suriname, Bolivia, Guyana, Trinidad and Tobago (Trinidad only), Brazil, Panama, Venezuela, Colombia, Paraguay, Ecuador, Peru The Foreign Office site said: "Where a Yellow Fever Vaccination Centre (YFVC) is unable to provide Yellow Fever vaccine during this vaccine shortage, the YFVC is expected to proactively research alternative supplies in their locality and direct travellers accordingly (this should be done for travellers who ring for advice and for travellers who attend for face to face consultation if vaccination is required promptly). "YFVCs will help travellers seeking YF vaccine at this time of vaccine shortage by: Ensuring an individual risk assessment is undertaken, and that YF vaccination is appropriate Signposting the traveller to possible alternative YFVC which are listed on the NaTHNaC YFVC locator database Contacting vaccine "distributors on behalf of the traveller. Some vaccine distributors may hold information on YFVC with vaccine availability" Check if you're at risk of yellow fever You can get yellow fever if you're bitten by an infected mosquit o. The mosquitoes that carry the yellow fever virus bite during the day. Yellow fever is very common in certain parts of the world, including: parts of sub-Saharan Africa (the area below the Sahara desert) parts of South America, including Trinidad and Tobago parts of Central America Yellow fever is not found in the UK, Europe, Asia, Australia, New Zealand or the Pacific Islands. How to lower your risk of yellow fever If you're travelling to an area where yellow fever is found, there are some things you can do to avoid being bitten by mosquitoes. wear long-sleeved clothing and trousers to cover your arms and legs, particularly during early morning and early evening use insect repellent on your skin (ideally one that contains the ingredient DEET) close windows and doors whenever possible, or use blinds or screens sleep under a mosquito net treated with insecticide, including during the day Symptoms of yellow fever Yellow fever symptoms usually start 3 to 6 days after being bitten by an infected mosquito, but sometimes they can take longer to appear. Some yellow fever symptoms are similar to flu, such as: high temperature headache feeling or being sick aches and pains loss of appetite feeling generally unwell These symptoms often last 3 or 4 days. But a small number of people get more serious symptoms within 24 hours of feeling better. More serious symptoms include: yellowing of your skin and eyes (jaundice) dark pee stomach pain bleeding from your eyes, nose, mouth or stomach – you may have blood in your vomit or poo These more serious symptoms can be fatal. For more information from the NHS on yellow feve r click here.
India Gazette
15-06-2025
- India Gazette
Bodies of 5 people killed in Kenya bus accident brought to Kerala
Kochi (Kerala) [India], June 15 (ANI): The bodies of five Indians who lost their lives in a bus accident in Kenya have been brought to Kerala, flying in a Qatar Airways flight and landing at Cochin International Airport on Sunday. Five locals from Kerala, including two children died in a bus accident in Kenya's capital on June 9, with 23 people being injured too. According to the Indian Embassy in Qatar, the Indians are undergoing treatment for any injuries in the country, while the post mortem of the five deceased have been completed. In the accident, Jasna (29), her daughter Ruhi Mehreen (1.5), Geetha Shoji Isaac (58), Riya Ann (41), and her daughter Tira Rodrigues (7) lost their lives and were brought back to Kerala. According to an official statement while there were initial concerns regarding the return of the bodies due to the Yellow fever vaccination certificate being required. However, after Kerala Chief Minister's request, the Central government has granted an exemption. 'The State Government, led by Chief Minister Pinarayi Vijayan, intervened promptly to facilitate the return of the bodies. Initially, there were concerns regarding the Yellow Fever vaccination certificate requirement for the deceased and their accompanying relatives. However, following the Chief Minister's intervention, the Central Government has granted a special exemption, allowing the bodies to be brought back without the certificate,' the statement read. Kerala industries minister P Rajeev and NORKA Roots representatives received the bodies on behalf of the state government and arranged transportation to their respective homes. The relatives of the deceased also accompanied the bodies on the flight. The bus accident occurred on June 9, when a tourist bus carrying 28 Indians, including the deceased, overturned in a valley in Naivasha, approximately 150 km from Nairobi. The group had arrived in Kenya from Qatar for a sightseeing tour. The Indian High Commission in Kenya noted that the road accident occurred at Ol Jororok-Nakuru Road in Nyandarua County, in which 5 Indian nationals lost their lives. In a post on X, the High Commission said that the consular team from the High Commission is on the ground and is in close contact with the local authorities to extend all necessary support. (ANI)
The Hindu
22-04-2025
- Health
- The Hindu
AIIMS Bibinagar inaugurates Telangana's second Yellow Fever vaccination centre
The All India Institute of Medical Sciences (AIIMS), Bibinagar, inaugurated its Yellow Fever Vaccination Centre under the Department of Community and Family Medicine on Monday. Yellow Fever, endemic to parts of Africa and South America, has no specific antiviral treatment. However, a single dose of the vaccine offers lifelong immunity, making vaccination an essential step for travellers heading to any of the 42 countries that mandate proof of Yellow Fever vaccination under International Health Regulations (IHR). AIIMS Bibinagar's vaccination centre will operate every Monday from 9 a.m to 11 a.m. Vaccination is appointment-based, with bookings to be made via email at yfvcaiimsbibinagar@ . The vaccine is priced at ₹300 per dose, the hospital authorities said. However, individuals with certain medical conditions such as allergies to egg proteins, pregnant women, those living with HIV/AIDS, or patients undergoing immunosuppressive therapies are not eligible for the vaccine. These individuals have been advised to consult the centre for possible exemption certificates, which may be required for international travel. To receive the vaccine, travellers must carry a valid passport, as it is required for the issuance of the International Certificate of Vaccination or Prophylaxis, commonly known as the Yellow Card.
Associated Press
10-03-2025
- Business
- Associated Press
Versatope Adds New Board Members
LOWELL, Mass., March 10, 2025 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today Edward Jordan and Sam Rasty have joined the company's Board of Directors and Jim Tartaglia joined the Scientific Advisory Board. Edward P. Jordan, MBA is the Chief Commercial Officer for XSpray Pharma, a clinical stage biotechnology company focused on advancing oncology care. He leads the USA-based efforts inclusive of commercial operations, supply, manufacturing and medical affairs for the anticipated approval and launch of advanced oncology products. The first of these is Dasynoc, which aims to bolster the clinical efficacy of the chronic myeloid leukemia drug Dasatinib while benefiting a wider patient population. Previously, Ed held various Chief Commercial and Operations Officer roles at Humanigen, DBV Technologies, AMAG Pharmaceuticals, Teva Pharmaceuticals, and Merck (Schering-Plough). He received dual Bachelor of Science Degrees from the University of Rhode Island and his MBA from Southern New Hampshire University. Sam Rasty, PhD, MBA is currently serving as Chief Business Officer at Sensorium Therapeutics, a Boston area biotech focused on the discovery and development of first-in-class therapies for neuropsychiatric and neurological diseases. Previously, he was Interim Chief Executive Officer of Sequence Bio, a genomics and precision medicine company in Canada, and President and Chief Executive Officer of PlateletBio, a pioneering cell therapy biotech company in the Boston area. He served as Chief Operating Officer and one of the early employees of Homology Medicines. His earlier career spanned a variety of leadership roles at Shire plc, Endo Pharmaceuticals and GlaxoSmithKline, focused on R&D, new product planning, commercial strategy, marketing and business development. Dr. Rasty earned a PhD in Biochemistry / Molecular Virology from Louisiana State University, completed a postdoctoral research fellowship in Molecular Genetics at the University of Pittsburgh School of Medicine and received an MBA from Villanova University. The company also announced today that James Tartaglia, PhD joined its Scientific Advisory Board (SAB). Dr. Tartaglia is an internationally recognized vaccine R&D leader with over 30 years of experience in industry, including contributions to partnerships with private sector, government and international agencies. In his role as Global Head of Vaccine Development and Life Cycle Management at Sanofi, Dr. Tartaglia was responsible for a vaccine portfolio of 25 projects extending from phase I/II through life cycle management in the areas of influenza, pediatric combination vaccines, RSV, rabies, Yellow Fever, pneumococcal and meningococcal vaccines. Over his career, Dr. Tartaglia has been involved in the licensure of 20 vaccines in veterinary and human health. 'Versatope is now a clinical-stage biotechnology company and the addition of our new board members will help us in advancing our commercialization and business strategy,' said Christopher Locher, PhD and CEO of Versatope. 'I am very pleased with the progress our R&D scientists have made to this point and welcome the new board members to the Versatope team.' About Versatope Therapeutics Versatope Therapeutics, Inc., is a clinical-stage biotechnology company located in Lowell, MA at the University of Massachusetts' M2D2 biotech incubator. Versatope discovers and develops new vaccines and therapeutics with its novel delivery platform. The technological foundation uses nano-scale vesicles derived from genetically modified variants of microbial cells. Versatope expresses membrane-bound vaccine antigens (epitopes) for vaccines or antibody-derived fragments (paratopes) for drug delivery with cell-specific targeting. Learn more about Versatope Therapeutics at
